KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Raw Materials: 2011-2013

Historic Raw Materials for Pacira BioSciences (PCRX) over the last 1 years, with Jun 2013 value amounting to $3.4 million.

  • Pacira BioSciences' Raw Materials rose 2.64% to $3.4 million in Q2 2013 from the same period last year, while for Jun 2013 it was $3.4 million, marking a year-over-year increase of 2.64%. This contributed to the annual value of $4.1 million for FY2012, which is 373.43% up from last year.
  • According to the latest figures from Q2 2013, Pacira BioSciences' Raw Materials is $3.4 million, which was up 25.21% from $2.7 million recorded in Q1 2013.
  • In the past 5 years, Pacira BioSciences' Raw Materials registered a high of $4.5 million during Q3 2012, and its lowest value of $862,000 during Q4 2011.
  • In the last 3 years, Pacira BioSciences' Raw Materials had a median value of $3.4 million in 2012 and averaged $3.2 million.
  • Data for Pacira BioSciences' Raw Materials shows a peak YoY surged of 373.43% (in 2012) over the last 5 years.
  • Pacira BioSciences' Raw Materials (Quarterly) stood at $862,000 in 2011, then skyrocketed by 373.43% to $4.1 million in 2012, then rose by 2.64% to $3.4 million in 2013.
  • Its Raw Materials was $3.4 million in Q2 2013, compared to $2.7 million in Q1 2013 and $4.1 million in Q4 2012.